Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024
22 February 2024 - 11:00PM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose
mission is to develop medicines that meaningfully improve and
extend the lives of patients facing deadly diseases, today
announced that it will host a live conference call and audio
webcast on Thursday, February 29, 2024 at 8:30 a.m. ET to report
financial results for the fourth quarter and full-year ended
December 31, 2023, and to provide a business overview.
To access the live conference call, please dial (646) 307-1963
(domestic) or (800) 715-9871 (international) at least five minutes
prior to the start time, and refer to conference ID 6933453. A live
audio webcast of the call will also be available on the Investors’
section of the Company's website, www.chimerix.com. An archived
webcast will be available on the Chimerix website approximately two
hours after the event.
About Chimerix
Chimerix is a biopharmaceutical company with a mission to
develop medicines that meaningfully improve and extend the lives of
patients facing deadly diseases. The Company’s most advanced
clinical-stage development program, ONC201, is in development for
H3 K27M-mutant glioma.
CONTACT:
Will O’ConnorStern Investor
Relations212-362-1200will@sternir.com
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Dec 2023 to Dec 2024